Therapeutic Response

v::NTRK3 status confers therapeutic sensitivity to Larotrectinib in patients with Any solid tumor.

Statements

Source and description
Vitrakvi (larotrectinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Larotrectinib's product label specifies to select patients for therapy based on an FDA-approved test.
Vitrakvi (larotrectinib) [product monograph]. HC. Health Canada approved larotrectinib for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.